Bristol-Myers Squibb Company (BMY) Holdings Held by Pineno Levin & Ford Asset Management Inc.
Pineno Levin & Ford Asset Management Inc. continued to hold its stake in Bristol-Myers Squibb Company (NYSE:BMY) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,952 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. Pineno Levin & Ford Asset Management Inc.’s holdings in Bristol-Myers Squibb were worth $220,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in the stock. Welch Investments LLC boosted its holdings in Bristol-Myers Squibb by 3.9% during the first quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 79 shares during the last quarter. Blue Chip Partners Inc. boosted its holdings in Bristol-Myers Squibb by 0.8% during the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 17 shares during the last quarter. Proficio Capital Partners LLC boosted its holdings in Bristol-Myers Squibb by 29.6% during the first quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 504 shares during the last quarter. American National Bank boosted its holdings in Bristol-Myers Squibb by 11.7% during the second quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 225 shares during the last quarter. Finally, Heritage Trust Co bought a new position in Bristol-Myers Squibb during the first quarter worth about $123,000. Hedge funds and other institutional investors own 68.84% of the company’s stock.
Shares of Bristol-Myers Squibb Company (NYSE BMY) opened at 63.65 on Tuesday. The company has a market cap of $104.38 billion, a PE ratio of 23.25 and a beta of 1.19. The firm has a 50-day moving average price of $62.78 and a 200 day moving average price of $56.98. Bristol-Myers Squibb Company has a 1-year low of $46.01 and a 1-year high of $66.10.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.01. The business had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The company’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.69 earnings per share. On average, equities analysts anticipate that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be issued a $0.39 dividend. The ex-dividend date of this dividend is Thursday, October 5th. This represents a $1.56 annualized dividend and a yield of 2.45%. Bristol-Myers Squibb’s payout ratio is currently 56.73%.
COPYRIGHT VIOLATION NOTICE: “Bristol-Myers Squibb Company (BMY) Holdings Held by Pineno Levin & Ford Asset Management Inc.” was posted by Daily Political and is owned by of Daily Political. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.dailypolitical.com/2017/10/17/bristol-myers-squibb-company-bmy-holdings-held-by-pineno-levin-ford-asset-management-inc.html.
In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the transaction, the senior vice president now owns 46,297 shares in the company, valued at $2,777,820. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Theodore R. Samuels II purchased 6,000 shares of the business’s stock in a transaction on Wednesday, August 2nd. The stock was purchased at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the acquisition, the director now owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The disclosure for this purchase can be found here. 0.23% of the stock is currently owned by corporate insiders.
BMY has been the topic of a number of recent analyst reports. UBS AG restated a “buy” rating and set a $72.00 target price (up previously from $62.00) on shares of Bristol-Myers Squibb in a report on Friday, October 6th. Vetr upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 target price on the stock in a report on Monday, October 9th. BMO Capital Markets restated a “sell” rating and set a $49.00 target price on shares of Bristol-Myers Squibb in a report on Monday, September 4th. BidaskClub upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Finally, Jefferies Group LLC restated a “buy” rating and set a $66.00 target price (up previously from $63.00) on shares of Bristol-Myers Squibb in a report on Thursday, August 24th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and ten have assigned a buy rating to the company. Bristol-Myers Squibb has an average rating of “Hold” and an average target price of $63.21.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.